Cargando…

Oncolytic herpes virus G47Δ works synergistically with CTLA-4 inhibition via dynamic intratumoral immune modulation

Oncolytic virus therapy can increase the immunogenicity of tumors and remodel the immunosuppressive tumor microenvironment, leading to an increased antitumor response to immune-checkpoint inhibitors. Here, we investigated the therapeutic potential of G47Δ, a third-generation oncolytic herpes simplex...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sugawara, Kotaro, Iwai, Miwako, Ito, Hirotaka, Tanaka, Minoru, Seto, Yasuyuki, Todo, Tomoki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8413837/ https://www.ncbi.nlm.nih.gov/pubmed/34514094 http://dx.doi.org/10.1016/j.omto.2021.05.004

Ejemplares similares

Efficacy and safety of a third-generation oncolytic herpes virus G47Δ in models of human esophageal carcinoma
por: Yajima, Shoh, et al.
Publicado: (2021)

Efficacy of a Third-Generation Oncolytic Herpes Virus G47Δ in Advanced Stage Models of Human Gastric Cancer
por: Sugawara, Kotaro, et al.
Publicado: (2020)

Neoadjuvant use of oncolytic herpes virus G47Δ prevents local recurrence after insufficient resection in tongue cancer models
por: Inoue, Kosuke, et al.
Publicado: (2023)

Oncolytic herpes virus G47Δ injected into tongue cancer swiftly traffics in lymphatics and suppresses metastasis
por: Uchihashi, Toshihiro, et al.
Publicado: (2021)

Neoadjuvant Use of Oncolytic Herpes Virus G47Δ Enhances the Antitumor Efficacy of Radiofrequency Ablation
por: Yamada, Tomoharu, et al.
Publicado: (2020)

Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial
por: Todo, Tomoki, et al.
Publicado: (2022)

Fusion peptide is superior to co-expressing subunits for arming oncolytic herpes virus with interleukin 12
por: Fukuhara, Hiroshi, et al.
Publicado: (2023)

A phase I/II study of triple-mutated oncolytic herpes virus G47∆ in patients with progressive glioblastoma
por: Todo, Tomoki, et al.
Publicado: (2022)

Overcoming resistance of stroma-rich pancreatic cancer with focal adhesion kinase inhibitor combined with G47Δ and immune checkpoint inhibitors
por: Yamada, Tomoharu, et al.
Publicado: (2022)

Efficacy of cancer-specific anti-podoplanin CAR-T cells and oncolytic herpes virus G47Δ combination therapy against glioblastoma
por: Chalise, Lushun, et al.
Publicado: (2022)

Triple‐mutated oncolytic herpes virus for treating both fast‐ and slow‐growing tumors
por: Fukuhara, Hiroshi, et al.
Publicado: (2021)

Modulation of the Intratumoral Immune Landscape by Oncolytic Herpes Simplex Virus Virotherapy
por: Yin, Jie, et al.
Publicado: (2017)

Efficacy of a third-generation oncolytic herpes simplex virus in neuroendocrine tumor xenograft models
por: Matsushima, Hideyuki, et al.
Publicado: (2019)

Treatment of human hepatocellular carcinoma by the oncolytic herpes simplex virus G47delta
por: Wang, Jiani, et al.
Publicado: (2014)

Third‐generation oncolytic herpes simplex virus inhibits the growth of liver tumors in mice
por: Nakatake, Richi, et al.
Publicado: (2018)

Efficacy of a third-generation oncolytic herpes simplex virus in refractory soft tissue sarcoma xenograft models
por: Hatta, Masahiko, et al.
Publicado: (2022)

Anti-tumor effect of oncolytic herpes simplex virus G47delta on human nasopharyngeal carcinoma
por: Wang, Jia-Ni, et al.
Publicado: (2011)

Designing herpes viruses as oncolytics
por: Peters, Cole, et al.
Publicado: (2015)

Oncolytic virus therapy: A new era of cancer treatment at dawn
por: Fukuhara, Hiroshi, et al.
Publicado: (2016)

Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade
por: Ju, Fei, et al.
Publicado: (2022)

A novel fusogenic herpes simplex virus for oncolytic virotherapy of squamous cell carcinoma
por: Takaoka, Hiroo, et al.
Publicado: (2011)

Oncolytic herpes simplex virus and temozolomide synergistically inhibit breast cancer cell tumorigenesis in vitro and in vivo
por: Fan, Jingjing, et al.
Publicado: (2021)

Oncolytic herpes simplex virus and immunotherapy
por: Ma, Wenqing, et al.
Publicado: (2018)

Entry of Oncolytic Herpes Simplex Virus into Human Squamous Cell Carcinoma Cells by Ultrasound
por: Okunaga, Shusuke, et al.
Publicado: (2015)

Discovery of Intratumoral Oncolytic Bacteria Toward Targeted Anticancer Theranostics
por: Goto, Yamato, et al.
Publicado: (2023)

Genetically coating oncolytic herpes simplex virus with CD47 allows efficient systemic delivery and prolongs virus persistence at tumor site
por: Fu, Xinping, et al.
Publicado: (2018)

Retargeting Strategies for Oncolytic Herpes Simplex Viruses
por: Campadelli-Fiume, Gabriella, et al.
Publicado: (2016)

Intratumoral OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: a multicenter, phase I/II clinical trial
por: Zhang, Bo, et al.
Publicado: (2021)

Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell–mediated glioma rejection
por: vom Berg, Johannes, et al.
Publicado: (2013)

Oncolytic herpes viruses, chemotherapeutics, and other cancer drugs
por: Braidwood, Lynne, et al.
Publicado: (2013)

Oncolytic Herpes Simplex Virus-Based Therapies for Cancer
por: Aldrak, Norah, et al.
Publicado: (2021)

Inhibition of colorectal cancer liver metastasis in BALB/c mice following intratumoral injection of oncolytic herpes simplex virus type 2 for the induction of specific antitumor immunity
por: Zhang, Wen, et al.
Publicado: (2019)

Oncolytic adenoviruses synergistically enhance anti-PD-L1 and anti-CTLA-4 immunotherapy by modulating the tumour microenvironment in a 4T1 orthotopic mouse model
por: Zhang, Huan, et al.
Publicado: (2021)

Anti-CTLA-4 antibodies in cancer immunotherapy: selective depletion of intratumoral regulatory T cells or checkpoint blockade?
por: Tang, Fei, et al.
Publicado: (2018)

Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy
por: Rehman, Hasan, et al.
Publicado: (2016)

Oncolytic Zika virus promotes intratumoral T cell infiltration and improves immunotherapy efficacy in glioblastoma
por: Chen, Lishu, et al.
Publicado: (2022)

Evaluation of the stability and intratumoral delivery of foreign transgenes encoded by an oncolytic Foamy Virus vector
por: Budzik, Karol M., et al.
Publicado: (2022)

Defects in intratumoral arginine metabolism attenuate the replication and therapeutic efficacy of oncolytic myxoma virus
por: Dryja, Parker, et al.
Publicado: (2023)

Presage of oncolytic virotherapy for oral cancer with herpes simplex virus
por: Yura, Yoshiaki
Publicado: (2017)

The Current State of Oncolytic Herpes Simplex Virus for Glioblastoma Treatment
por: Nguyen, Hong-My, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7svc5jd4odmbso6h0vi1sfklvo